Contact
Please use this form to send email to PR contact of this press release:
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
TO:
Please use this form to send email to PR contact of this press release:
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
TO: